Related references
Note: Only part of the references are listed.Isoniazid level and flu-like symptoms during rifapentine-based tuberculosis preventive therapy: A population pharmacokinetic analysis
Ming-Chia Lee et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2023)
High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus
Ryan T. Jarrett et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)
Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure
Agathe Beranger et al.
CLINICAL INFECTIOUS DISEASES (2022)
Development of population pharmacokinetics model of isoniazid in Indonesian patients with tuberculosis
Soedarsono Soedarsono et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2022)
Parametric and Nonparametric Methods in Population Pharmacokinetics: Experts' Discussion on Use, Strengths, and Limitations
Sylvain Goutelle et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2022)
Population Pharmacokinetics and Pharmacodynamics of Isoniazid and its Metabolite Acetylisoniazid in Chinese Population
Bing Chen et al.
FRONTIERS IN PHARMACOLOGY (2022)
Population Pharmacokinetics and Pharmacodynamics of Isoniazid and its Metabolite Acetylisoniazid in Chinese Population
Bing Chen et al.
FRONTIERS IN PHARMACOLOGY (2022)
Drug exposure of first-line anti-tuberculosis drugs in China: A prospective pharmacological cohort study
Yazhou Gao et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Population Pharmacokinetics of Levetiracetam: A Systematic Review
Zi-ran Li et al.
CLINICAL PHARMACOKINETICS (2021)
Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs
Marieke G. G. Sturkenboom et al.
CLINICAL PHARMACOKINETICS (2021)
Population pharmacokinetics of oxcarbazepine: a systematic review
Yue-Ting Chen et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2021)
Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile
Vianney Tuloup et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis
Yong-Soon Cho et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Population Pharmacokinetics and Significant Under-Dosing of Anti-Tuberculosis Medications in People with HIV and Critical Illness
Prakruti S. Rao et al.
ANTIBIOTICS-BASEL (2021)
Population Pharmacokinetic Properties of Antituberculosis Drugs in Vietnamese Children with Tuberculous Meningitis
Navarat Panjasawatwong et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Cross-resistance of isoniazid, para-aminosalicylic acid and pasiniazid against isoniazid-resistant Mycobacterium tuberculosis isolates in China
Guilian Li et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2020)
Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China
Wei Jing et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Pregnant South African Women with Tuberculosis and HIV
Mahmoud Tareq Abdelwahab et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy
Jesper Sundell et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Longitudinal Pharmacokinetic-Pharmacodynamic Biomarkers Correlate With Treatment Outcome in Drug-Sensitive Pulmonary Tuberculosis: A Population Pharmacokinetic-Pharmacodynamic Analysis
Frank Kloprogge et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Population pharmacokinetics of isoniazid and dose recommendations in Mexican patients with tuberculosis
Ana Patricia Huerta-Garcia et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2020)
Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid
Maxwell T. Chirehwa et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?
Christine Sekaggya-Wiltshire et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis
Anushka Naidoo et al.
PHARMACOGENOMICS (2019)
Pharmacokinetics of isoniazid: The good, the bad, and the alternatives
Emily R. Erwin et al.
TUBERCULOSIS (2019)
Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India
Blessed Winston Aruldhas et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?
Ilaria Motta et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2018)
Evaluation of the Adequacy of WHO Revised Dosages of the First-Line Antituberculosis Drugs in Children with Tuberculosis Using Population Pharmacokinetic Modeling and Simulations
Yasuhiro Horita et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications
Benjamin Guiastrennec et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Assessing the Combined Antibacterial Effect of Isoniazid and Rifampin on Four Mycobacterium tuberculosis Strains Using In Vitro Experiments and Response-Surface Modeling
Charlotte Genestet et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation
Christopher Vinnard et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Understanding and applying pharmacometric modelling and simulation in clinical practice and research
Joseph F. Standing
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
The challenges of pharmacokinetic variability of first-line anti-TB drugs
Bella Devaleenal Daniel et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)
Isoniazid: A Review of Characteristics, Properties and Analytical Methods
Guilherme Felipe dos Santos Fernandes et al.
CRITICAL REVIEWS IN ANALYTICAL CHEMISTRY (2017)
Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis
Neesha Rockwood et al.
CLINICAL INFECTIOUS DISEASES (2017)
Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in ChildrenWith Tuberculosis With and Without HIV Coinfection
Awewura Kwara et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2016)
HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients
Neesha Rockwood et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Role of Inflammatory and Oxidative Stress, Cytochrome P450 2E1, and Bile Acid Disturbance in Rat Liver Injury Induced by Isoniazid and Lipopolysaccharide Cotreatment
Hozeifa Mohamed Hassan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis
L. Mota et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2016)
Isoniazid metabolism and hepatotoxicity
Pengcheng Wang et al.
ACTA PHARMACEUTICA SINICA B (2016)
Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling
Nitin Mehrotra et al.
DRUG METABOLISM AND DISPOSITION (2016)
Population Pharmacokinetic Analysis of Isoniazid, Acetylisoniazid, and Isonicotinic Acid in Healthy Volunteers
Kok-Yong Seng et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement
Salmaan Kanji et al.
CLINICAL PHARMACOKINETICS (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
Larissa Shamseer et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
Larissa Shamseer et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
What do we learn from repeated population analyses?
Stephen B. Duffull et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania
Paolo Denti et al.
PLOS ONE (2015)
Reporting a Population Pharmacokinetic-Pharmacodynamic Study: A Journal's Perspective
Kris M. Jamsen et al.
CLINICAL PHARMACOKINETICS (2014)
Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update
Abdullah Alsultan et al.
DRUGS (2014)
Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses
Simbarashe P. Zvada et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Expression of NAT2 in immune system cells and the relation of NAT2 gene polymorphisms in the anti-tuberculosis therapy in Mexican mestizo population
R. Salazar-Gonzalez et al.
MOLECULAR BIOLOGY REPORTS (2014)
NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy
Junichi Azuma et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children
G. Ramachandran et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2013)
Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes
Jotam G. Pasipanodya et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Reduced Antituberculosis Drug Concentrations in HIV-Infected Patients Who Are Men or Have Low Weight: Implications for International Dosing Guidelines
Helen McIlleron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
The Pharmacogenetics of NAT2 Enzyme Maturation in Perinatally HIV Exposed Infants Receiving Isoniazid
Rui Zhu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes
David W. Hein et al.
PHARMACOGENOMICS (2012)
Isoniazid Pharmacokinetics, Pharmacodynamics, and Dosing in South African Infants
Jennifer J. Kiser et al.
THERAPEUTIC DRUG MONITORING (2012)
Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint
Stephen B. Duffull et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients
Justin J. Wilkins et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Arylamine N-Acetyltransferase 2 (NAT2) Genetic Diversity and Traditional Subsistence: A Worldwide Population Survey
Audrey Sabbagh et al.
PLOS ONE (2011)
Mechanistic Basis of Using Body Size and Maturation to Predict Clearance in Humans
Brian J. Anderson et al.
DRUG METABOLISM AND PHARMACOKINETICS (2009)
Worldwide distribution of NAT2 diversity:: Implications for NAT2 evolutionary history
Audrey Sabbagh et al.
BMC GENETICS (2008)
Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms
Elena Garcia-Martin
CURRENT DRUG METABOLISM (2008)
Gender differences in pharmacological response
Gail D. Anderson
EPILEPSY IN WOMEN: THE SCIENTIFIC BASIS FOR CLINICAL MANAGEMENT (2008)
Adverse events and treatment interruption in tuberculosis patients with and without HIV coinfection
R. A. M. Breen et al.
THORAX (2006)
Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?
M Kinzig-Schippers et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis
D Yee et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
Differences in N-acetylation genotypes between Caucasians and black south africans: implications for cancer prevention
A Loktionov et al.
CANCER DETECTION AND PREVENTION (2002)
Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms
AJ Fretland et al.
PHARMACOGENETICS (2001)
Population pharmacokinetics/pharmacodynamics modeling: Parametric and nonparametric methods
R Jelliffe et al.
THERAPEUTIC DRUG MONITORING (2000)
Pharmacogenetics of the human arylamine N-acetyltransferases
DM Grant et al.
PHARMACOLOGY (2000)
Share Paper
